Clinical trials: Retina
Diabetes, Diabetic Retinopathy
Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device
Diabetes affects over 37 million Americans and over 530 million people globally. Each diabetic patient needs at least one retinal exam per year starting immediately at the time of diagnosis if they have Type II diabetes (and…
- Conditions
- Diabetes, Diabetic Retinopathy, Diabetic Macular Edema, Diabetic Eye Problems
- Trial name
- NCT05368623
- Testing
- Color fundus photograph, Optical Coherence Tomography (OCT) of the retina, Mydriatic Agent
- Where
- 3 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- RETINA-AI Health, Inc.
Mucolipidosis Type IV
The Natural History and Pathogenesis of Mucolipidosis Type IV
Mucolipidosis Type IV (ML-IV) is a metabolic disorder that causes mental and motor retardation as well as visual impairment. There is storage of material in practically all the cells of the body, causing problems in the brain and…
- Trial name
- NCT00015782
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Trial name
- NCT06864988
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 94 sites in United States, Canada
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Primary Open Angle Glaucoma, Secondary Open Angle Glaucoma
Protective Effect of Phenytoin on Glaucoma
since glaucoma is considered an optic neuropathy, new treatments for glaucoma are being continuously investigated, including neuroprotection.
- Conditions
- Primary Open Angle Glaucoma, Secondary Open Angle Glaucoma, Narrow-Angle Glaucomas, Normal Tension Glaucoma
- Trial name
- NCT00739154
- Where
- Israel
- Volunteers
- 200 people
- Sponsor
- Rabin Medical Center
Dry Age-related Macular Degeneration, Geographic Atrophy
First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration
The study is designed to identify the maximum tolerated dose (MTD) for intravitreal (IVT) administration of GEM103 in subjects with geographic atrophy (GA) secondary to dry AMD.
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease
- Trial name
- NCT04246866
- Testing
- GEM103
- Where
- 12 sites in United States
- Volunteers
- 12 people
- Sponsor
- Gemini Therapeutics, Inc.
Proliferative Diabetic Retinopathy, Diabetic Macular Edema
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy
The purpose of the study is to find out if treatment with an intravitreal injection of triamcinolone or an intravitreal injection of ranibizumab can prevent loss of vision caused by panretinal photocoagulation treatment.
- Trial name
- LRTforDME+PRP (NCT00445003)
- Testing
- Ranibizumab, Triamcinolone Acetonide, Focal/grid laser
- Where
- 56 sites in United States
- Volunteers
- 333 people
- Sponsor
- Jaeb Center for Health Research
Age-related Macular Degeneration
Evaluate the Quality of Life of Patients With AMD
Age-related macular degeneration (AMD) is a major cause of deep visual acuity loss. Because of progressive deterioration of the macula, patients with AMD complain about progressive visual problems that can impair their quality of…
- Trial name
- QUASAR (NCT03242083)
- Testing
- quality of life questionnaire
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Hypertension
Hypertension and Retinal Microvascular Dysfunction
Hypertension is a worldwide health care burden that affects the structure and function of the macro- and microcirculation. Non-invasive vascular biomarkers are essential to timely diagnose end organ damage to improve…
- Trial name
- HyperVasc (NCT04763005)
- Testing
- HIIT exercise intervention, Physical activity recommendations
- Where
- Switzerland
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Basel
Dry Age Related Macular Degeneration
The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD
To evaluate the safety and tolerability of human somatic cell nuclear transfer embryonic stem cell derived retinal pigmented epithelial(SCNT-hES-RPE) cellular therapy in patients with advanced dry AMD
- Trial name
- NCT03305029
- Testing
- SCNT-hES-RPE Cells
- Where
- South Korea
- Volunteers
- 3 people
- Sponsor
- CHA University
Diabetic Retinopathy
Correlation Between HBA1c Level and Thickness of Both Macula and Choroid in Patients With Type 2 Diabetes Mellitus
Diabetic retinopathy (DR) is a frequent cause of visual impairment, and the leading cause of blindness in those of working age, but it develops silently along years, producing symptoms only in late stages.
- Trial name
- NCT05778370
- Testing
- Swept Source Optical Coherence Tomography(Topcon DRI Triton)
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Assiut University
Macular Degeneration
Identification and Treatment of Feeder Vessels in Macular Degeneration
This study will try to identify and treat feeder vessels in age-related macular degeneration. The macula is the part of the retina in the back of the eye that determines central or best vision.
- Trial name
- NCT00018070
- Testing
- Angiography, Laser Treatment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)
Retinal Vein Occlusion, Macular Edema
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Antagonists of the vascular endothelial growth factor (VEGF) pathway are effective in treating macular edema resulting from retinal vein occlusion (RVO).
- Trial name
- CRAVE (NCT01428388)
- Testing
- Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Barnes Retina Institute
Healthy Middle-aged Subjects, Age Range Was 18 to 31 Years
Impact of Exercise on Retinal Microvascular Regulation Measured by Dynamic Vessel Analysis in Healthy Individuals
Objective The investigators assessed the acute impact of physical exercise on retinal vessel regulation. This might be of clinical importance if retinal vessel regulation is examined with the very sensitive method of the dynamic…
- Conditions
- Healthy Middle-aged Subjects, Age Range Was 18 to 31 Years, Caucasian Whites, Males and Females
- Trial name
- NCT01297868
- Testing
- exercise
- Where
- Germany
- Sponsor
- University Medicine Greifswald
Low Vision
Design and Clinical Evaluation of a Smartphone-based Low Vision Enhancement System
The primary objective is to compare the effectiveness and adverse side-effects of the virtual bioptic telescope and virtual projection screen in a new head-mounted video-based low vision enhancement system (LVES) with a wide…
- Trial name
- eLVES (NCT03728660)
- Testing
- Virtual bioptic magnification with large field of view, Full field magnification with small field of view
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Johns Hopkins University
Retinoblastoma
Topotecan Episcleral Plaque for Treatment of Retinoblastoma
This single site, single-arm, non-randomized, dose escalation phase I toxicity clinical trial will assess primarily the safety and secondarily the efficacy of episcleral topotecan in patients with active de novo or residual or…
- Trial name
- STEP-RB (NCT04428879)
- Testing
- Topotecan Episcleral Plaque
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- The Hospital for Sick Children
Age-related Macular Degeneration
RBM-007 in Subjects witH ExudatIve Age-related Macular Degeneration
This is an open label, non-controlled, dose-escalating study assessing the safety, tolerability, and bioactivity of a single intravitreal (i.vt.) injection of RBM-007 in approximately nine subjects with exudative age-related…
- Trial name
- SUSHI (NCT03633084)
- Testing
- RBM-007 Injectable Solution
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Ribomic USA Inc
Refractory Neuroblastoma, Relapsed Neuroblastoma
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
- Conditions
- Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma
- Trial name
- GPC2 (NCT05650749)
- Testing
- GPC2 CAR T cells
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stephan Grupp MD PhD
Conjunctivitis, Glaucoma
Feasibility Study and Preliminary Application Study on Iris OCTA
All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens. The main outcomes are iris blood flow density and vascular density.
- Conditions
- Conjunctivitis, Glaucoma, Myopia, Diabetic Retinopathy
- Trial name
- NCT03631108
- Testing
- OCTA (ZEISS)
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Maculopathy
Assessment Of Diabetic Maculopathy Changes After Phacoemulsification by Using Optical Coherence Tomography
Investigators aimed to assess the macular changes with OCT after uncomplicated phacoemulsification surgery in diabetic patients with non proliferative diabetic retinopathy (NPDR) at the time of surgery and the effect of…
- Trial name
- Maculopathy (NCT05547789)
- Testing
- non steroidal anti inflammatory drugs
- Where
- 2 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
Central Serous Chorioretinopathy
Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy
The purpose of this study is to evaluate the effectiveness as well as the detrimental influence of half-dose and half-fluence modification of verteporfin photodynamic therapy (PDT) for the treatment of prolonged unresolved…
- Trial name
- NCT01019668
- Testing
- Verteporfin PDT, half-dose, verteporfin PDT, half-fluence
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Shin Kong Wu Ho-Su Memorial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.